Evaluation of the anti-tumoural effects of Sorafenib and Regorafenib on endometrial, prostate and thyroid neoplasias.

Sorafenib and Regorafenib reduce thyroid hyperplasias induced by the loss of phosphatase and tensin homolog deleted on chromosome 10 (PTEN).

This is the first study that correlates the response to multikinase inhibitors with a specific mutation.

This is the first report characterising the response to Regorafenib in thyroid, prostate and endometrial neoplasias.